The Tripled Biotech Big Money Is Still Piling Into

30‑Second Take

Here is the setup. On Tuesday, 106,605 Moderna call options were bought, roughly 35% above the typical daily volume of 78,801 contracts. That is a real signal, not noise.

The timing matters. Fall vaccine season is ramping up right now, with flu shots, updated COVID boosters, and RSV vaccines all in the mix. That is the annual window in which MRNA has to prove it can still generate revenue.

The stock nearly tripled in August after the FDA cleared Moderna's standalone mRNA flu shot, and it has been consolidating since, sitting roughly 15% under the high it set on that move. So you are not buying a forgotten name here — you are buying the pause after a re-rating, ahead of the season that has to justify it.

You are not chasing a moonshot here. You are betting that a freshly re-rated mRNA leader gets a seasonal tailwind while option flow tells you someone else is already there.

Trade Setup

Time frame: Swing to medium-term (2 to 4 months)
Edge type: Institutional positioning + seasonal catalyst

Snapshot Table

Chart

1-Month Trading Summary: MRNA is up roughly 170% over the past month. It gapped from the low $60s to $174 in a single session on the August flu-shot clearance, then settled into a wide $138 to $158 band.

The chart is a post-gap consolidation, not a fresh breakout, but the range is tightening and the call-buying spike is the kind of ingredient that shows up before the next leg. If you want an entry, add on any dip toward the $140 area rather than paying up on green candles.

Bull Case 

Why It Works

Moderna is not the growth darling it was in 2021. You know that. The market knows that. What has been missed is that management has cut costs aggressively, the combo flu/COVID vaccine (mRNA-1083) has already been authorized in the EU, and Moderna's standalone mRNA flu shot cleared the FDA in August 2026.

The fall vaccine season is now a real commercial test of whether those approvals translate into revenue.

The Street modeled a slow, boring recovery. The options market on Tuesday did not agree.

The Catalysts

Every year, roughly September through December, respiratory vaccine sales spike. That is when MRNA either meets its number or misses it. Expectations right now are on the floor, and any beat on booster uptake or early commercial traction for the newly approved flu shot lands on a stock the market is still trying to price.

Stack that with the ongoing rollout of the mRNA flu shot and EU-authorized combo vaccine, and you have multiple catalysts hitting inside the same window.

What The Numbers Say

When 106,000 calls trade in a single session, 35% above the typical run rate, on a stock this size, it is almost always institutional. Retail does not move that much premium. Somebody is betting on movement between now and expiry, and you should be paying attention.

Cost discipline is the other half. Moderna has been slashing expenses for over a year, and cash burn has narrowed meaningfully. The company can afford to wait for the pipeline to mature without a dilutive raise, which takes one of the biggest bear-case risks you face off the table.

Your play: build a starter position in the $150 zone. Add on any pullback to $140. Watch the October vaccine sales chatter. If the fall commercial launch data lands clean, this thing can retest the $176 high and possibly beyond.

Bear Case 

What Could Break It

Don't romanticize this one. Moderna is still burning cash and the mRNA story has taken real damage since 2022. Vaccine demand keeps normalizing lower, and the COVID franchise is now a maintenance business, not a growth engine, so treat any bounce as a trade, not a thesis.

The pipeline outside of respiratory vaccines has yet to deliver a breakthrough. If the fall numbers disappoint, the reason to own this shrinks fast.

The Valuation Risk

Not every options spike marks an entry. Sometimes big buyers are hedging existing longs or rolling calendars, so you cannot assume Tuesday's call flow is one-directional bullish conviction.

Competition is also very much alive. Pfizer is in this market, Novavax has a boring but functional platform, and updated boosters face real uptake questions if CDC or new administration recommendations shift. Reimbursement dynamics could pinch pricing right when you need volume to save the print.

How To Size It

MRNA sits about 15% below its 52-week high and multiples above the $22 washout low. Most of that gain arrived in one August session, which means it can come back out just as quickly. If the fall campaign underperforms, giving back a large chunk of the move is a real possibility, not a scare quote.

Do not size this like a conviction long. Treat it as a 2 to 4-month catalyst trade. Set a mental stop below $135. If it breaks that, the thesis is wrong, and you get out.

Quick Checklist 

✅ Thesis still valid after today's close
✅ Volume confirms move above key levels
✅ Catalyst date double-checked (fall vaccine campaign kickoff and commercial uptake data from recently approved mRNA flu shot and EU-authorized combo vaccine)

Deep‑Dive Links

• Latest earnings report

• Analyst ratings and price targets

• Short interest data

• Company profile and investor relations

  

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha